

WHO WE ARE







FROM MAPS...





...TO MAPS GROUP


29,8

2024

87%

2024


27,5



IL DOMANI È GIÀ QUI.



OUR HISTORY IN REVENUES





OUR FUTURE

5,40 €



Michele Mombelli Michele.Mombelli@tpicap.com

4,64€




Michele Filipping mfilipping@ktepartners.com

5,30 €



Marco Opipari research@websim.it





WHAT WE DO







PROMOTING AND LEVERAGING THE BEST PATIENT EXPERIENCE

PATIENT EXPERIENCE

(ITALIAN LEADER)

Use our patient experience solutions:

20% of the 508 PUBLIC HOSPITALS

100% of Italy's 5 LARGEST PRIVATE GROUPS



HUMANITAS
















FROM DIGITAL NATIVE TO TRADITIONALIST: ONE PLATFORM FOR A UNIVERSAL EXPERIENCE

ANALOGICAL PATIENT



Age: > 70 Years Total patient: 45%

Total population: 25%

PHYGITAL PATIENT



Age: 50 - 69 Years Total patient: 35%

Total population: 35%

DIGITAL PATIENT



Age: 18 - 49 Years

Total population: 40%

Total patient: 30%




A TASTE OF OUR PATIENT EXPERIENCE

ANALOGICAL TOUCHPOINT

PHYGITAL TOUCHPOINT

DIGITAL TOUCHPOINT






A TASTE OF OUR DATA DRIVEN GOVERNANCE: SHORTEN WAITING LISTS

OFFER MANAGEMENT





Performance monitoring, Real-time availability, Comparative analysis of Demand and Offer



Patented AI-based evaluation of appropriateness of requests, Management by Objectives, Audits, Evaluation of success of specific actions







DEMAND MANAGEMENT

Distrette Q	Agenda Q					Valori									
						tégg	1000	6692	1900	17800	Ottre	Artes Prestan	Ecount	EcoCap	EcoMan
utale distretti						46	100	1155	730	1386	3243	100	1.015	512	4
CARPS						33	29	255	180	398	874	42	184	110	
CASTELFRA	NCO EMBLIA	EN883-1-VISITA ENDOCRINOLOGIO					- 1	34	31	32	8)			3	
					rb. c/o Casa della Saluta OFE) VIBITA EHIDO	1	3	31	'47	47	- 92			7	
		RX888-6 - ECOGRAFIA ADDOME (RAL												- 3	
		RXI988-16 - ECO TIRÓIDE (RADIOLOS			on artis			4.6				1		- 8	
		RX857 - PG - SCO ADDOME SRV PO RX867-1 SCO TOATSRV POLIAMBUL			(2.0			29					35	-	
		RX657-1 COMMESSA LLINGA 600 CA			MERRA ECO CARO COLLO									- 5	
		ROBET-S - COMMESSA LUNGA ECO N												2	
MIRANDOLA	l,					16	13	-318	121	276	148	138	184	72	
MODENA						2		373	166	434	579	79	294	169	
PWULLD						1		326	88	64		37	73	1.6	
BASSUDLO								29	27	- 81		158	215	93	
AJORDIA 6							19	71	42	68	266	84	22	35	
i Prioritoff	C. Aplenda		Q. Ricerca Br	nanche	Q. Riseroa Prostazioni										
	Accords Date:	Santaria Locale di Medena	e di Madema Altris AGRIEGI - VISITA ARGICILOGICA (2198-98)		81 - VELTE ANGEOLOGICA (2198-981) - ViaAng										
	DLOma & Civ	w.	Avestmia		AG00001 - VIIITA ANGIOLOGICA ILICCESSI	W (1949.991	-Valrg8u								
	D1.Hecoma		Cardinoga		AG08893 - INIEZIONE INTRAVENOSA DI SO										
	D1 Losem		Drivingia pene	est)	AGROPES - VISITA ANGIOLOGICA PER COMPLETAMENTO DIAGNOSTICO - Non assecuta al aggregativa										
	D15 Mests				AGRERES - VIDEOMICROSCOPULA SONDA O										



HOSPITAL INFORMATION SYSTEM





OUTPATIENT MANAGEMENT





INPATIENT MANAGEMENT

MANAGEMENT OF OPERATIVE PROCESSES OF HOSPITALS WITH AI-BASED SUPPORT OF CLINICAL PRACTICE



DIAGNOSTIC INFORMATION SYSTEM





LABORATORY TESTS



PATHOLOGICAL ANATOMY



DIAGNOSTIC IMAGING

STREAMLINED AND SECURE EXECUTION OF DIAGNOSTIC SERVICES

ENERGY PRODUCTS







MAPS ENERGY: A KEY GROWTH STRATEGY

BUSINESS MODULES OPTIMIZE Reduce costs, consumption and GHG emissions AGGREGATE Energy Communities FLEXIBILITY





DIGITAL ENERGY ENABLER FOR REAL TIME **MONITORING** AND **OPTIMIZATION**:



CROSS MARKETS






AI-POWERED OMNICHANNEL CONTACT CENTER

Cloud-based AI CONTACT CENTER PLATFORM that:

- Connects with customers seamlessly across all digital and voice channels.
- Uses Gen-Al assistants to automate conversations and deliver instant, accurate responses.
- Intelligently routes interactions to human agents when needed.
- Makes communication faster, easier, and more cost-efficient.



WHAT'S NEXT





WHAT'S NEXT

Leverage our leadership position and product quality to meet the growing market demand for an improved **PATIENT EXPERIENCE** across the country



Build on our experience with large-scale **PRIVATE HOSPITALS** to meet the demand for digitalization and automation of healthcare processes in **MEDIUM-SIZED** hospitals



MERGE &

ACQUISITIONS



Apply our expertise in managing complex data to deliver **DATA- DRIVEN GOVERNANCE** for our clients

Use our unique combinatio of **GEN-AI, OMNICHANNEL**, and **PATIENT EXPERIENCE** to accelerate the digitalization of patient relationship management



WHAT'S NEXT

Address the growing needs for **CARBON NEUTRALITY** of buildings seconding the EU Green Deal



Capitalize on our ready-made **ENERGY EFFICIENCY** solutions for a reduced time-to-market and highest margin business



ACQUISITIONS



Leverage our product leadership in **ENERGY COMMUNITY**Management software to become the undisputed reference player in this market

Expand into INTERNATIONAL MARKETS to scale our offering and fully seize opportunities in the EU energy transition landscape.


FINANCIAL RESULTS







SEASONALITY AS A KEY TO INTERPRETING OUR RESULTS








ORGANIC INCREASE IN REVENUES

RECORD-LEVEL PROFITABILITY


HALVED DEBT









+8% vs 2023



Total Revenues



2024 REVENUES INCREASE BREAKDOWN






2024 PROFITABILITY BREAKDOWN

	2024	Maps Healthcare	Maps Energy	Maps ESG	Maps Lab
TOTAL REVENUES	28.931k€	18.459 k€	2.363 k€	2.994 k€	1.055 k€
OPERATING MARGIN	53% 15.232 k€	56% 10.353k€	44% 693 k€	50% 1.490 k€	46% 2.750 k€
COMMERCIAL COSTS	14% 4.052k€	13% 2.464k€	46% 733 k€	18% 535 k€	5% 320 k€
ADMINISTRATIVE COSTS	16% 4.725 k€	14% 2.578 k€	32% 513 k€	18% 542 k€	18% 1.092 k€
EBITDA	25% 7.361 k€	29% 5.312 k€	10% 228 k€	15% 451 k€	23% (1.370 k€)

2024 NET FINANCIAL POSITION EVOLUTION BREAKDOWN





2024 RESULTS SPLIT BY BUSINESS UNITS

/.000€	MAPS HEALTHCARE	MAPSENERGY	MAPSESG	MAPSLAB	Total
Operating Revenues	18,406	1,582	2,994	5,950	28,932
- o/w Recurrent Fees	7,369	481	1,730	2,175	11,756
- o/w Services	11,036	1,101	1,264	3,775	17,176
Other Revenues	54	781	39	32	906
Total Revenues	18,459	2,363	3,032	5,982	29,837
Production Costs	(8,107)	(889)	(1,504)	(3,200)	(13,700)
- o/w Personnel Costs	(5,848)	(526)	(1,136)	(2,503)	(10,013)
- o/w Direct Services Costs	(2,259)	(363)	(368)	(697)	(3,687)
Operating Margin	10,353	693	1,490	2,750	15,232
Operating Margin (%)	56%	44%	50%	46%	53%
Commercial Costs	(2,464)	(733)	(535)	(320)	(4,052)
R&D Costs	(1,213)	(1,192)	(379)	(277)	(3,061)
R&D Costs capitalized	1,213	1,192	379	277	3,061
Administrative Costs	(2,578)	(513)	(542)	(1,092)	(4,725)
EBITDA	5,312	228	451	1,370	7,361
EBITDA Margin (%)	29%	10%	15%	23%	25%
Recurrent Fees (%)	40%	30%	58%	37%	41%
Revenue from Proprietary Products	18,406	1,492	2,994	2,413	25,305
Revenue from Proprietary Products (%)	100%	94%	100%	41%	87%




1h 2025 IN A GLANCE

REVENUE GROWTH PUSHED BY PRODUCT PERFORMANCE


MARGIN COMPRESSION REFLECTS
THE IMPACT OF SPECIFIC CLIENTS

NFP REFLECTED THE IMPACT OF THE JUNE M&A DEAL





22% 19% 1h 2024 VS 1h 2025




Total Revenues

EBITDA Margin

Net Financial Position



1H 2025 REVENUES INCREASE BREAKDOWN





1H 2025 MARGINALITY BREAKDOWN

	1h 2025	Healthcare Products	Energy Products	Other Products	Custom Projects
TOTAL REVENUES	15.780 k€	10.575 k€	1.263 k€	2.887 k€	1.055 k€
OPERATING MARGIN	43% 6.498 k€	51% 5.361 k€	23% 180 k€	32% 908 k€	5% 50 k€
COMMERCIAL COSTS	13% 1.898 k€	12% 1.247k€	49% 370 k€	8% 240 k€	4% 41 k€
ADMINISTRATIVE COSTS	16% 2.360 k€	13% 1.327k€	40% 308 k€	15% 418 k€	30% 308 k€
EBITDA	19% 2.974 k€	28% 2.977 k€	1% 9 k€	10% 280 k€	- (292 k€)

1H 2025 NET FINANCIAL POSITION EVOLUTION BREAKDOWN

IFRS 16 Financial debt





1h 2025 OVERALL RESULTS

€/1,000	1h 2025	1h 2024
Total Revenues	15,780	14,712
Internally generated fixed assets	1,542	1,411
Value of Production	17,322	16,123
Cost of goods sold	(1,844)	(715)
Staff	(8,724)	(8,577)
Services	(3,257)	(3,235)
Operating fixed costs	(522)	(424)
Operating Costs	(14,348)	(12,951)
EBITDA	2,974	3,171
EBITDA Margin (%)	19%	22%
Amortization & Depreciation	(1,685)	(1,672)
Not recurring costs	(68)	(211)
EBIT	1,220	1,288
Financial Management & Subsidiaries	(315)	(302)
EBT	905	985
Tax	(344)	(408)

€/1,000	1h 2025	2024	
Fixed Assets	32,361	27,834	
Inventory	9,890	7,194	
Receivables	11,150	10,697	
Payables	(3,171)	(2,345)	
Other Current assets & liability	(5,079)	(3,282)	
Total Funds	(7,804)	(7,414)	
Net Capital Invested	37,346	32,686	
Net Capital Invested Shareholders' Equity	37,346 26,339	32,686 25,731	
Shareholders' Equity	26,339	25,731	
Shareholders' Equity - Long Term Debt	26,339 9,210	25,731 6,179	
Shareholders' Equity - Long Term Debt - Short Term Debt	26,339 9,210 6,231	25,731 6,179 7,125	



1h 2025 RESULTS SPLIT FOR BUSINESS UNITS

/.000 €	MAPS HEALTHCARE	MAPSENERGY	MAPS LAYERS CROSS MARKET SOLUTIONS	MINDLAB	Total
Operating Revenues	10,411	761	2,864	1,053	15,089
- o/w Recurrent Fees	4,248	275	882	25	5,430
- o/w Services	6,163	486	1,982	1,028	9,658
Other Revenues	164	502	22	2	691
Total Revenues	10,575	1,263	2,887	1,055	15,780
Production Costs	(5,049)	(582)	(1,956)	(1,003)	(8,590)
- o/w Personnel Costs	(3,747)	(466)	(589)	(717)	(5,519)
- o/w Direct Services Costs	(1,303)	(116)	(1,367)	(285)	(3,072)
Operating Margin	5,361	179	908	50	6,498
Operating Margin (%)	51%	23%	32%	5%	43%
Commercial Costs	(1,247)	(370)	(240)	(41)	(1,898)
R&D Costs	(713)	(520)	(258)	(4)	(1,496)
Capitalized Costs	739	525	266	9	1,537
Administrative Costs	(1,327)	(308)	(418)	(308)	(2,360)
EBITDA	2,977	9	280	(292)	2,974
EBITDA Margin (%)	28%	1%	10%		19%
Recurrent Fees (%)	41%	36%	31%	2%	36%
Revenue from Proprietary Products	10,411	722	2,864	41	14,038
Revenue from Proprietary Products (%)	100%	95%	100%	4%	93%



mapsgroup.it

Maps S.p.A. Via Paradigna 38/A, 43122 Parma (PR), Italy

Email: info@mapsgroup.it

Pec: mapsspa@actaliscertymail.it

Telefono: +39 0521 052300

P.IVA / C.F: 01977490356 - R.E.A. PR-240225

